The role of anti-Müllerian hormone in predicting clomiphene citrate resistance in women with polycystic ovarian syndrome

Gülşen, Mehmet Serdar; Ulu, İpek; Köpük, Şule Yıldırım; Grover, Kiran

doi:10.1080/09513590.2018.1499085

Cited by 16 publications

(14 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, available data suggest the role of AMH in inhibiting folliculogenesis by interference with the concentration and the actions of FSH in the ovaries [45]. some previous studies [46, 47] reported a reduced ovarian response in PCOS women when AMH level is above a threshold value (4.7 ng/ml). Therefore, PCOS patients require dose step up during ART cycles, and are at higher risk for severe OHSS.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the umbilical cord Blood’s anti-Mullerian hormone level in the newborns of mothers with polycystic ovary syndrome (PCOS) and healthy mothers

et al. 2019

View full text Add to dashboard Cite

BackgroundPolycystic ovary syndrome (PCOS) is one of the most common endocrine diseases. At present, the cause of the disease is not fully understood, but many studies have shown that PCOS is associated with genetic and environmental factors. The present study aimed to assess the umbilical cord blood’s Anti-mullerian hormone (AMH) level in the newborns of mothers suffering from PCOS comparing to healthy mothers.MethodsThis prospective cohort study was conducted on 120 pregnant women with PCOS, who were selected through Rotterdam criteria, and 60 healthy pregnant women as the control group. The subjects in each group were divided into obese and non-obese mothers according to their body mass index (BMI) before pregnancy. The cord blood samples were collected from the offsprings on the time of childbirth. Finally, the circulating concentrations of AMH in both sexes of the newborns were determined by specific assays.ResultsThe research results showed that the blood level of AMH was higher in the neonates of obese mothers with PCOS comparing to the controls (P < 0.001). Mean AMH level was higher in male neonates born from non-obese PCOS mothers than in the controls (P < 0.001); however, there was not a significant difference in the level of AMH in female neonates between these two groups (P = 0.264). Also the level of the above biomarker was higher in both sexes of the neonates belonging to obese PCOS mothers compared with the neonates born from non-obese PCOS mothers (P < 0.001).Conclusion(s)It can be said that the cord blood AMH level of neonates from obese women with PCOS is higher than that in the newborns of non-obese PCOS mothers. Further longitudinal studies are needed to confirm the clinical findings of the present research.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of the umbilical cord Blood’s anti-Mullerian hormone level in the newborns of mothers with polycystic ovary syndrome (PCOS) and healthy mothers

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In this study, women who ovulated in response to CC had significantly lower AMH than women who did not ovulate in response to CC. compatible with the prior study of Maharan A and co-workers [18] which evaluates the effect of AMH on response rates of CC in sixty females with PCOS and found high circulatory AMH negatively correlated with the chance of ovulation and with the previous study of Wenyan who evaluates the effect of AMH level on the success of CC therapy in 81 anovulatory with PCOS and proves that with high AMH are more likely to not respond to cc treatment [19] and also with the study of Gülşen et al, who found that serum AMH level was seen to be useful in the prediction of CC resistance with a sensitivity of 66% and a specificity of 89% when the threshold for AMH concentration was >12.38 ng/ml in PCOS patients [20].…”

Section: Discussionmentioning

confidence: 98%

Anti-mullerian Hormone Serum Level as a Predictor of Responsiveness to Clomiphene Citrate Therapy in Iraqi Women with PCOS

Rashid

Bardan

2022

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Ovulation induction in polycystic ovarian syndrome is one of the most common interventions used in the treatment of infertility and prediction of the response is very important. Although the serum anti-mullerian hormone (AMH) concentrations are known to be a reliable predictor of ovarian response in in vitro fertilization, in women with polycystic ovary syndrome (PCOS) with a higher level of AMH ovulation induction by clomiphene citrate may be not enough to increase the level of follicle-stimulating hormone and reduce the intraovarain AMH to a level that compatible with the restoration of ovulation. AIM: Our study aimed to identify those females who will respond to treatment and the starting dose of anti-mullerian hormone serum level as a predictor of responsiveness to clomiphene citrate therapy in Iraqi women with PCOS. METHODS: 79 females with polycystic ovarian syndrome were included in the study. AMH serum concentrations were determined on the second or 3rd day of the early follicular phase of the menstrual cycle before initiating clomiphene citrate in the first treatment cycle. RESULTS: The females were falling-out into two groups according to their response to treatment. The patient who ovulated had a significantly lower AMH level among responders 7.89 +−3.2 compared to non-responder 9.41 +−3.27. The women who responded at 50 mg dose had lower AMH 6.56 +−2.2 compared to women who responded at 100mg clomiphene citrate had AMH of 8.74 +−3 with optimum cutoff value for AMH is 6.25 to respond. CONCLUSION: Serum AMH level measurement prior to treatment initiation in women with PCOS may be a useful method for predicting the outcome of clomiphene citrate treatment, and for each specific ethnic group, there is a cutoff value for AMH above which the response to clomiphene citrate is impaired.

show abstract

“…When analyzing available literature, it is essential to note that the studies cover different populations, apply different AMH kits, and have different androgen concentrations and body mass index (BMI). These and other factors such as small sample size and retrospective design of the studies could influence the results [73][74][75][76][77][78][79][80][81]. It has been demonstrated that serum AMH levels are positively correlated with an antral follicular count, free testosterone, and luteinizing hormone levels.…”

Section: Amh and Ovarian Response In Women With Pcosmentioning

confidence: 99%

“…The high AMH concentration could influence the sensitivity of follicles to gonadotropin stimulation. Most studies indicate the usefulness of AMH measurement in predicting CC response [74][75][76][77][78][79].…”

Section: Amh and Ovarian Response In Women With Pcosmentioning

confidence: 99%

Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS

Rudnicka

Kunicki

Calik-Ksepka

et al. 2021

IJMS

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive-aged women. It is characterized by chronic anovulation, hyperandrogenism, and the presence of polycystic ovary in ultrasound examination. PCOS is specified by an increased number of follicles at all growing stages, mainly seen in the preantral and small antral follicles and an increased serum level of Anti-Müllerian Hormone (AMH). Because of the strong correlation between circulating AMH levels and antral follicle count on ultrasound, Anti-Müllerian Hormone has been proposed as an alternative marker of ovulatory dysfunction in PCOS. However, the results from the current literature are not homogeneous, and the specific threshold of AMH in PCOS and PCOM is, therefore, very challenging. This review aims to update the current knowledge about AMH, the pathophysiology of AMH in the pathogenesis of PCOS, and the role of Anti-Müllerian Hormone in the treatment of this syndrome.

show abstract

The role of anti-Müllerian hormone in predicting clomiphene citrate resistance in women with polycystic ovarian syndrome

Cited by 16 publications

References 15 publications

Comparison of the umbilical cord Blood’s anti-Mullerian hormone level in the newborns of mothers with polycystic ovary syndrome (PCOS) and healthy mothers

Comparison of the umbilical cord Blood’s anti-Mullerian hormone level in the newborns of mothers with polycystic ovary syndrome (PCOS) and healthy mothers

Anti-mullerian Hormone Serum Level as a Predictor of Responsiveness to Clomiphene Citrate Therapy in Iraqi Women with PCOS

Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS

Contact Info

Product

Resources

About